百奥泰(688177) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 206,555,604.43, representing a 27.83% increase compared to CNY 161,591,937.51 in the same period last year[3] - The net profit attributable to shareholders was a loss of CNY 93,330,977.90, an improvement from a loss of CNY 118,958,055.48 year-over-year[3] - The net loss for Q1 2025 was ¥93,330,977.90, an improvement from a net loss of ¥118,958,055.48 in Q1 2024[20] - The company reported a total comprehensive loss of -93,667,998.14 RMB for Q1 2025, compared to -119,035,070.61 RMB in Q1 2024, showing a reduction in losses[35] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 79,416,905.66, a significant recovery from a negative cash flow of CNY 64,803,155.03 in the previous year[3] - Operating cash flow for Q1 2025 was ¥79,416,905.66, a significant improvement from -¥64,803,155.03 in Q1 2024[25] - Cash inflow from operating activities in Q1 2025 was 389,351,258.04 RMB, compared to 220,047,817.51 RMB in Q1 2024, reflecting a growth of about 77%[37] - The total cash and cash equivalents at the end of Q1 2025 reached 472,171,686.61 RMB, up from 292,801,722.94 RMB at the end of Q1 2024, representing an increase of approximately 61.4%[38] Research and Development - R&D expenses totaled CNY 180,224,489.76, which is a 5.01% increase from CNY 171,622,215.16, accounting for 87.25% of revenue, down from 106.21%[3] - R&D expenses increased to ¥180,224,489.76 in Q1 2025, compared to ¥171,622,215.16 in Q1 2024, marking a growth of 5.8%[19] - The company continues to focus on R&D and market expansion strategies to improve future performance[19] Assets and Liabilities - Total assets increased by 6.35% to CNY 2,345,641,403.78 from CNY 2,205,537,745.47 at the end of the previous year[4] - Total assets increased to ¥2,345,641,403.78 in Q1 2025 from ¥2,205,537,745.47 in Q1 2024, representing a growth of 6.4%[17] - Total liabilities rose to ¥1,730,911,199.49 in Q1 2025, up from ¥1,497,448,743.34 in Q1 2024, indicating an increase of 15.6%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,526[9] - Guangzhou Qixi Group Co., Ltd. holds 38.64% of the shares, making it the largest shareholder[10] - Therabio International Limited is the second largest shareholder with 11.39% of the shares[10] Government Support - The company received government subsidies amounting to CNY 6,233,653.05, which positively impacted the financial results[5] Other Financial Metrics - The weighted average return on equity was -14.11%, a decrease of 3.79 percentage points from -10.32% in the previous year[3] - Basic and diluted earnings per share for Q1 2025 were both -¥0.23, compared to -¥0.29 in Q1 2024[21] - The company reported a net profit margin improvement with a net income of ¥6,228,094.38 in Q1 2025, compared to ¥2,518,299.72 in Q1 2024[33]